Updated:
Nivagen Pharmaceuticals
Nivagen Pharmaceuticals is a Sacramento-based company founded in 2009. It develops, acquires, and sells generic prescription and over-the-counter products for...
Nivagen Pharmaceuticals
Nivagen Pharmaceuticals is a Sacramento-based company founded in 2009. It develops, acquires, and sells generic prescription and over-the-counter products for the North American market. The company has secured $26 million in total funding.
General information
Firm type
Specialty Pharmaceuticals (Generics and Sterile Injectables)
Year founded
2009
Location
Region
North America
Country
United States
City
Sacramento
Corporate office
Sacramento, CA, United States
Sector focus
Frequently asked questions
Who owns Nivagen Pharmaceuticals?
Ownership of Nivagen Pharmaceuticals is not publicly disclosed. The firm is privately held, based in Sacramento, California. No principals or institutional backers are named in available records.
What type of pharmaceutical products does Nivagen focus on?
Nivagen Pharmaceuticals is described as a company in the generic and specialty pharmaceutical space. Specific product pipelines, therapeutic areas, or approved drugs are not publicly documented.
Is Nivagen Pharmaceuticals active in investment or venture capital?
No. Nivagen Pharmaceuticals is a pharmaceutical operating company, not an investment vehicle. Its activities likely center on drug development and commercialization rather than external capital deployment. No AUM or investment mandates are disclosed.
Where is Nivagen Pharmaceuticals headquartered?
The firm is headquartered in Sacramento, California, United States. No additional offices or international presence are indicated in public sources.
How can I verify Nivagen Pharmaceuticals' regulatory compliance?
Pharmaceutical firms in the U.S. are regulated by the FDA. Nivagen's regulatory status, including any approved drugs or facilities, is not publicly listed in commonly accessible databases. Interested parties may check FDA databases for corporate filings or product approvals.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: